Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
We plan to conduct a prospective, single blinded, randomized clinical trial to assess the impact of combined spinal-epidural dosing on the success rate of, and patient satisfaction during, external version for breech fetal position and the incidence of vaginal vs. Cesarean delivery.
The research aim of this project is to determine the ideal neuraxial dosing strategy to maximize success of external cephalic version (ECV).
The research questions, does a combined spinal-epidural (CSE) of a higher dose result in greater success in converting a breech presentation to vertex during external cephalic version (ECV).
The hypotheses of this project is that CSE at higher dose will result in greater ECV success than analgesic dosing.
The research significance:Increasing the success and comfort of ECV for fetal malpresentation may help decrease the cesarean section rate.
At term 2 to 3% of singleton pregnancies are in breech presentation. Many of these deliveries are managed by cesarean delivery due to higher neonatal morbidity associated with vaginal breech delivery. However, cesarean delivery, the safer option for the baby, is associated with a higher incidence of maternal complications for both the current and subsequent pregnancies. External cephalic version (ECV) is a procedure commonly used to attempt to manually rotate the fetus into vertex position. This facilitates vaginal delivery and thus avoids higher maternal and/or neonatal complications. (Hofmeyr Cochrane Review) Obstetricians generally perform versions after 36 weeks gestational age with a reportable success rate of 50-80%, depending on several factors, including patient characteristics. (Fortunato, Zhang, ACOG 1997 ECV) The most common technique involves external manipulation of the fetal position preceded by pharmacologic uterine relaxation. Until recently, pain relief was generally provided in the form of intravenous opioids such as fentanyl. A more efficacious form of analgesia is the use of neuraxial opioids and local anesthetics (neuraxial analgesia), a technique commonly used for labor and delivery analgesia.
Two non-randomized studies of neuraxial analgesia compared to systemic analgesia found improved success of external cephalic version in the neuraxial analgesia groups.(Carlan, Birnbach) Three randomized trials have conflicting results: 2 demonstrate an increase in success, one shows no difference. (Dugoff, Schorr, Mancuso) None of these studies have blinded the obstetrician performing the version. In 2010, Lavoie and colleagues completed a meta-analysis looking at ECV performed under analgesic and anesthetic neuraxial doses. The analgesic dose included spinal bupivacaine and epidural dosing. The anesthestic groups gave higher doses of spinal or epidural bupivacaine. This meta-analysis suggested that those patients who had received an anesthetic dose of had more successful ECV. All published studies examining pain outcomes have demonstrated that neuraxial analgesia results in greater patient comfort during this procedure.
The American College of Obstetricians and Gynecologists (ACOG) has stated, "Currently there is not enough evidence to make a recommendation favoring or opposing anesthesia during ECV (external cephalic version) attempts."
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Drug:Group 2.5 | Active Comparator | Administration of 2.5 mg bupivacaine |
|
| Group 5 | Active Comparator | Administration of 5 mg bupivacaine. |
|
| Group 7.5 | Active Comparator | Administration of 7.5mg bupivacaine. |
|
| Group 10 | Active Comparator | Administration of 10 mg bupivacaine. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Group 2.5 | Drug | Administration of bupivacaine 2.5 mg. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Success Rate of External Cephalic Version | Rates of successful version evaluated among the 4 dose groups. | Completion of the procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Mode of Delivery | To time of delivery | |
| Indication of Cesarean Delivery | To time of delivery | |
| Pain Score During the Procedure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Walega, MD | Northwestern University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Prentice Women's Hospital | Chicago | Illinois | 60611 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 12076384 | Background | Hofmeyr GJ. Interventions to help external cephalic version for breech presentation at term. Cochrane Database Syst Rev. 2002;(2):CD000184. doi: 10.1002/14651858.CD000184. | |
| 3288930 | Background | Fortunato SJ, Mercer LJ, Guzick DS. External cephalic version with tocolysis: factors associated with success. Obstet Gynecol. 1988 Jul;72(1):59-62. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A total of 240 patients were enrolled and allocated to one of four bupivicaine dose groups
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Drug:Group 2.5 | Administration of 2.5 mg bupivacaine Group 2.5: Administration of bupivacaine 2.5 mg. |
| FG001 | Group 5 | Administration of 5 mg bupivacaine. Group 5: Administration of 5 mg bupivacaine |
| FG002 | Group 7.5 | Administration of 7.5mg bupivacaine. Group 7.5: Administration of 7.5 mg bupivacaine |
| FG003 | Group 10 | Administration of 10 mg bupivacaine. Group 10: Administration of 10mg bupivacaine. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Drug:Group 2.5 | Administration of 2.5 mg bupivacaine Group 2.5: Administration of bupivacaine 2.5 mg. |
| BG001 | Group 5 | Administration of 5 mg bupivacaine. Group 5: Administration of 5 mg bupivacaine |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Success Rate of External Cephalic Version | Rates of successful version evaluated among the 4 dose groups. | Posted | Count of Participants | Participants | Completion of the procedure |
|
4 years
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Group 2.5 | Bupivicaine 2.5 mg | 0 |
Not provided
Not provided
The limitations include group allocation concealment and lack of a control group. The obstetrician's assessment of success, pain, anxiety, and fetus status may have prejudiced the decision to proceed or persist with external cephalic version.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Robert J McCarthy | Northwestern University | 312-695-4976 | r-mccarthy@northwestern.edu |
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| D000377 | Agnosia |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010468 | Perceptual Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D002045 | Bupivacaine |
| ID | Term |
|---|---|
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 | Aniline Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Group 5 | Drug | Administration of 5 mg bupivacaine |
|
|
| Group 7.5 | Drug | Administration of 7.5 mg bupivacaine |
|
|
| Group 10 | Drug | Administration of 10mg bupivacaine. |
|
|
pain score during the procedure (Visual Analog Score: VAS=0 no pain -100 worst pain imaginable, scale) |
| < 20 minutes |
| Abdominal Relaxation | Obstetrician rating of participants abdominal relaxation (Visual analog score: VAS score= 0 no relaxation- complete relaxation 100) | <20 minutes |
| 8336883 | Background | Zhang J, Bowes WA Jr, Fortney JA. Efficacy of external cephalic version: a review. Obstet Gynecol. 1993 Aug;82(2):306-12. |
| 9359456 | Background | ACOG practice patterns. External cephalic version. Number 4, July 1997. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1997 Oct;59(1):73-80. No abstract available. |
| 8067558 | Background | Carlan SJ, Dent JM, Huckaby T, Whittington EC, Shaefer D. The effect of epidural anesthesia on safety and success of external cephalic version at term. Anesth Analg. 1994 Sep;79(3):525-8. doi: 10.1213/00000539-199409000-00021. |
| 11473871 | Background | Birnbach DJ, Matut J, Stein DJ, Campagnuolo J, Drimbarean C, Grunebaum A, Kuroda MM, Thys DM. The effect of intrathecal analgesia on the success of external cephalic version. Anesth Analg. 2001 Aug;93(2):410-3, 4th contents page. doi: 10.1097/00000539-200108000-00035. |
| 10074976 | Background | Dugoff L, Stamm CA, Jones OW 3rd, Mohling SI, Hawkins JL. The effect of spinal anesthesia on the success rate of external cephalic version: a randomized trial. Obstet Gynecol. 1999 Mar;93(3):345-9. doi: 10.1016/s0029-7844(98)00456-6. |
| 9396908 | Background | Schorr SJ, Speights SE, Ross EL, Bofill JA, Rust OA, Norman PF, Morrison JC. A randomized trial of epidural anesthesia to improve external cephalic version success. Am J Obstet Gynecol. 1997 Nov;177(5):1133-7. doi: 10.1016/s0002-9378(97)70029-2. |
| 10775722 | Background | Mancuso KM, Yancey MK, Murphy JA, Markenson GR. Epidural analgesia for cephalic version: a randomized trial. Obstet Gynecol. 2000 May;95(5):648-51. doi: 10.1016/s0029-7844(99)00611-0. |
| 20127530 | Background | Lavoie A, Guay J. Anesthetic dose neuraxial blockade increases the success rate of external fetal version: a meta-analysis. Can J Anaesth. 2010 May;57(5):408-14. doi: 10.1007/s12630-010-9278-4. Epub 2010 Feb 3. |
| 19682886 | Background | Sullivan JT, Grobman WA, Bauchat JR, Scavone BM, Grouper S, McCarthy RJ, Wong CA. A randomized controlled trial of the effect of combined spinal-epidural analgesia on the success of external cephalic version for breech presentation. Int J Obstet Anesth. 2009 Oct;18(4):328-34. doi: 10.1016/j.ijoa.2009.02.006. Epub 2009 Aug 13. |
| BG002 | Group 7.5 | Administration of 7.5mg bupivacaine. Group 7.5: Administration of 7.5 mg bupivacaine |
| BG003 | Group 10 | Administration of 10 mg bupivacaine. Group 10: Administration of 10mg bupivacaine. |
| BG004 | Total | Total of all reporting groups |
| Participants |
|
| Sex/Gender, Customized | Count of Participants | Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| BMI | BMI is defined as the body mass divided by the square of the body height, and is universally expressed in units of kg/m^2, resulting from mass in kilograms and height in meters. | Median | Inter-Quartile Range | kg/m^2 |
|
| Estimated Gestational Age | Median | Inter-Quartile Range | days |
|
| Duration of Procedure | Median | Inter-Quartile Range | minutes |
|
| OG003 | Group 10 | Administration of 10 mg bupivacaine. Group 10: Administration of 10mg bupivacaine. |
|
|
| Secondary | Mode of Delivery | Posted | Number | count of participants | To time of delivery |
|
|
|
| Secondary | Indication of Cesarean Delivery | Posted | Count of Participants | Participants | To time of delivery |
|
|
|
| Secondary | Pain Score During the Procedure | pain score during the procedure (Visual Analog Score: VAS=0 no pain -100 worst pain imaginable, scale) | Posted | Median | Inter-Quartile Range | units on a scale | < 20 minutes |
|
|
|
| Secondary | Abdominal Relaxation | Obstetrician rating of participants abdominal relaxation (Visual analog score: VAS score= 0 no relaxation- complete relaxation 100) | Posted | Median | Inter-Quartile Range | units on a scale | <20 minutes |
|
|
|
| 60 |
| 0 |
| 60 |
| 0 |
| 60 |
| EG001 | Group 5 | Bupivicaine 5 mg | 0 | 60 | 0 | 60 | 0 | 60 |
| EG002 | Group 7.5 | Bupivicaine 7.5 mg | 0 | 59 | 0 | 59 | 0 | 60 |
| EG003 | Group 10 | Bupivicaine 10 mg | 0 | 60 | 0 | 60 | 0 | 60 |
Not provided
Not provided
| D019954 | Neurobehavioral Manifestations |
| D009422 | Nervous System Diseases |
| D000588 |
| Amines |
| Cesarean |
|
| Arrest of LAbor |
|
| Nonreassuring Fetal Status |
|
| Emergency |
|